Current therapeutic options in pediatric multiple sclerosis

Current Treatment Options in Neurology

Volumn 13, Issue 6, 2011, Pages 544-559

  Yeh, E Ann ^a  

^a CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALEFACEPT; BACLOFEN; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DIAZEPAM; ETANERCEPT; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; PALIFERMIN; PROVENGE; RITUXIMAB; TERIFLUNOMIDE; TETANUS TOXOID; THIOTEPA; UNINDEXED DRUG; VITAMIN D; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY DISORDER; APPETITE; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ASTHENIA; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; AUTOIMMUNE HEPATITIS; BACKACHE; BLEEDING; BLOOD PRESSURE LABILITY; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CARDIOTOXICITY; CATARACT; CHEST TIGHTNESS; CHILL; CHOLELITHIASIS; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; DEPRESSION; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM INJURY; DISORDERS OF LIPOPROTEIN METABOLISM; DIZZINESS; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DYSPNEA; ECCHYMOSIS; EDEMA; ERYTHEMA MULTIFORME; ESOPHAGITIS; EXERCISE; FATIGUE; FIBROSING ALVEOLITIS; FIBROSIS; FLU LIKE SYNDROME; FLUID RETENTION; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH INHIBITION; HALLUCINATION; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HEREDITARY MOTOR SENSORY NEUROPATHY; HIRSUTISM; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERPROTEINEMIA; HYPERTENSION; HYPERVISCOSITY SYNDROME; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; INFERTILITY; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; INTESTINE STENOSIS; INTRAOCULAR PRESSURE; KAPOSI SARCOMA; KIDNEY FAILURE; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG EDEMA; LUNG FUNCTION TEST; LYMPHADENOPATHY; MALIGNANT NEOPLASTIC DISEASE; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE HYPERTONIA; MYALGIA; MYOCARDITIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OCCUPATIONAL THERAPY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT COUNSELING; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSEUDOHYPONATREMIA; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; RIGOR; SEPSIS; SIDE EFFECT; SKIN ATROPHY; SKIN EDEMA; SODIUM RETENTION; SORE THROAT; SPASTICITY; SPEECH THERAPY; STEVENS JOHNSON SYNDROME; STOMATITIS; SUICIDAL IDEATION; SWEATING; SYNCOPE; TENDON RUPTURE; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THYROID DISEASE; TISSUE INJURY; TOOTH PAIN; TOXIC EPIDERMAL NECROLYSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; TREMOR; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY BLADDER FIBROSIS; URINARY TRACT INFECTION; URINE; URTICARIA; VAGINITIS; VASCULITIS; VASODILATATION; VERTIGO; VISUAL DISORDER; VOMITING; WALKING AID; WEIGHT GAIN;

EID: 81155159670     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0141-x     Document Type: Article

References (62)

1. B Banwell, et al. 2009 Incidence of acquired demyelination of the CNS in Canadian children Neurology 72 3 232 9 19153370 10.1212/01.wnl.0000339482.84392. bd 1:STN:280:DC%2BD1M%2Fot1Snug%3D%3D This study documents the incidence of acquired CNS demyelination using a country-wide cohort in Canada
2. T Chitnis, et al. 2009 Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States Mult Scler 15 5 627 31 19299440 10.1177/1352458508101933 1:STN:280:DC%2BD1M3ps1yjsA%3D%3D
3. F Hanefeld 2007 Pediatric multiple sclerosis: a short history of a long story Neurology 68 16 Suppl 2 S3 6 17438236 10.1212/01.wnl.0000259419.96311.54 (Pubitemid 46626000)
4. C Renoux, et al. 2007 Natural history of multiple sclerosis with childhood onset N Engl J Med 356 25 2603 13 17582070 10.1056/NEJMoa067597 1:CAS:528:DC%2BD2sXmslKjs7w%3D (Pubitemid 46961005)
5. A Ghezzi, et al. 2007 Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results Neurol Sci 28 3 127 32 17603763 10.1007/s10072-007-0804-2 1:STN:280:DC%2BD2szos1OnsA%3D%3D (Pubitemid 47039838)
6. SN Tenembaum MJ Segura 2006 Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis Neurology 67 3 511 3 16775230 10.1212/01.wnl.0000231137.24467.aa 1:CAS:528:DC%2BD28Xntl2msbw%3D (Pubitemid 44214986)
7. Y Mikaeloff, et al. 2001 Interferon-beta treatment in patients with childhood-onset multiple sclerosis J Pediatr 139 3 443 6 11562627 10.1067/mpd.2001.117004 1:CAS:528:DC%2BD3MXnslSls7o%3D (Pubitemid 32889524)
8. D Pohl, et al. 2005 Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a Neurology 64 5 888 90 15753430 10.1212/01.WNL.0000153570.33845.6A 1:CAS:528:DC%2BD2MXhtl2mtbs%3D (Pubitemid 40316332)
9. E Waubant, et al. 2001 Interferon beta-1a in children with multiple sclerosis is well tolerated Neuropediatrics 32 4 211 3 11571702 10.1055/s-2001-17370 1:STN:280:DC%2BD3MrisVelsA%3D%3D (Pubitemid 32895904)
10. EA Yeh, et al. 2011 Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis Arch Neurol 68 4 437 44 21149803 10.1001/archneurol.2010.325 This paper evaluates the use of first-line and second-line therapies for children with MS in a large US cohort
11. A Ghezzi, et al. 2005 Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study Mult Scler 11 4 420 4 16042224 10.1191/1352458505ms1206oa 1:CAS:528:DC%2BD2MXos1eitrk%3D (Pubitemid 40984236)
12. B Kornek, et al. 2003 Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis Neuropediatrics 34 3 120 6 12910434 10.1055/s-2003-41274 1:CAS:528:DC%2BD3sXntlKjt7w%3D (Pubitemid 36994400)
13. A Ghezzi, et al. 2010 Safety and efficacy of natalizumab in children with multiple sclerosis Neurology 75 10 912 7 20820002 10.1212/WNL.0b013e3181f11daf 1:CAS:528:DC%2BC3cXhtFaitrvI This prospective case series documents response to natalizumab in a cohort of 19 children with treatment-refractory disease
14. EA Yeh B Weinstock-Guttman 2010 Natalizumab in pediatric multiple sclerosis patients Ther Adv Neurol Disord 3 5 293 9 21179619 10.1177/1756285610381526 1:CAS:528:DC%2BC3cXhsF2jsr7M
15. B Kornek, et al. 2011 Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis Neuropediatrics 42 1 7 12 21557144 10.1055/s-0031-1275345 1:STN:280:DC%2BC3MvpslKhtg%3D%3D
16. N Makhani, et al. 2009 Cyclophosphamide therapy in pediatric multiple sclerosis Neurology 72 24 2076 82 19439723 10.1212/WNL.0b013e3181a8164c 1:CAS:528:DC%2BD1MXnt1OksLs%3D
17. M Karenfort, et al. 2009 Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis Dev Med Child Neurol 51 2 159 61 19191848 10.1111/j.1469-8749.2008.03246.x
18. L Kappos, et al. 2010 A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 5 387 401 20089952 10.1056/NEJMoa0909494 1:CAS:528:DC%2BC3cXhvVWltr4%3D
19. A Ghezzi, et al. 2010 The management of multiple sclerosis in children: a European view Mult Scler 16 10 1258 67 20685764 10.1177/1352458510375568
20. AT Waldman, et al. 2011 Management of pediatric central nervous system demyelinating disorders$$ consensus of United States neurologists J Child Neurol 26 6 675 82 21518802 10.1177/0883073810395141 This paper provides information from a survey of therapeutic practices among a group of child neurologists in the United States
21. I Takahashi, et al. 1997 Childhood multiple sclerosis treated with plasmapheresis Pediatr Neurol 17 1 83 7 9308985 10.1016/S0887-8994(97)80673-X 1:STN:280:DyaK2svlt1Gksw%3D%3D (Pubitemid 27387928)
22. S Schilling, et al. 2006 Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients Nervenarzt 77 4 430 8 16341736 10.1007/s00115-005-2019-1 1:STN:280:DC%2BD287otVOlsg%3D%3D
23. WS MacAllister, et al. 2005 Cognitive functioning in children and adolescents with multiple sclerosis Neurology 64 8 1422 5 15851734 10.1212/01.WNL.0000158474.24191.BC 1:STN:280:DC%2BD2M3hsleqsA%3D%3D (Pubitemid 40570512)
24. Yeh E, et al. Fatigue and depression are seen more frequently in children with pediatric demyelinating disorders than healthy controls. Presented at ECTRIMS 2011: Amsterdam, October 19-22, 2011.
25. WS MacAllister, et al. 2009 Fatigue and quality of life in pediatric multiple sclerosis Mult Scler 15 12 1502 8 19965517 10.1177/1352458509345902
26. E Mowry, et al. 2008 Health-related quality of life is reduced in children with early multiple sclerosis Mult Scler 14 Suppl 1 S147
27. WS MacAllister, et al. 2007 The psychosocial consequences of pediatric multiple sclerosis Neurology 68 16 Suppl 2 S66 9 17438240 10.1212/01.wnl. 0000259420.54635.63 1:STN:280:DC%2BD2s3ivFCguw%3D%3D (Pubitemid 46626007)
28. PJ Milla AD Jackson 1977 A controlled trial of baclofen in children with cerebral palsy J Int Med Res 5 6 398 404 338390 1:STN:280:DyaE1c%2FmsV2qsQ%3D%3D (Pubitemid 8220590)
29. A Mathew, et al. 2005 The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy J Trop Pediatr 51 2 109 13 15840761 10.1093/tropej/fmh095 (Pubitemid 40797012)
30. HA Engle 1966 The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study Dev Med Child Neurol 8 6 661 7 5339679 10.1111/j.1469-8749.1966.tb01824.x 1:STN:280:DyaF2s7otlGjsg%3D%3D
31. AD Goodman, et al. 2009 Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial Lancet 373 9665 732 8 19249634 10.1016/S0140-6736(09)60442-6 1:CAS:528:DC%2BD1MXisVOrtr4%3D
32. AD Goodman, et al. 2010 A phase 3 trial of extended release oral dalfampridine in multiple sclerosis Ann Neurol 68 4 494 502 20976768 10.1002/ana.22240 1:CAS:528:DC%2BC3cXhsVOrur7J
33. KW Rammohan, et al. 2002 Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study J Neurol Neurosurg Psychiatry 72 2 179 83 11796766 10.1136/jnnp.72.2.179 1:STN:280:DC%2BD38%2FntVKqtw%3D%3D (Pubitemid 34102149)
34. B Stankoff, et al. 2005 Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study Neurology 64 7 1139 43 15824337 10.1212/01.WNL.0000158272.27070.6A 1:CAS:528:DC%2BD2MXislSlsr8%3D
35. F Möller, et al. 2011 HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis Mult Scler 17 8 1002 9 21561959 10.1177/1352458511402410
36. J Biederman, et al. 2005 Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study Pediatrics 116 6 e777 84 16322134 10.1542/peds.2005-0617 (Pubitemid 46056456)
37. EM Mowry, et al. 2010 Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis Ann Neurol 67 5 618 24 20437559 1:CAS:528:DC%2BC3cXmvF2lsr0%3D This paper evaluates the relationship of vitamin D levels to relapse rate in pediatric MS in children seen at two MS centers in the United States
38. Yeh E, et al. Obesity as a risk factor for childhood onset demyelinating disorders. Presented at the American Academy of Neurology 2011, Honolulu, HI. P02.163.
39. Y Mikaeloff, et al. 2007 Parental smoking at home and the risk of childhood-onset multiple sclerosis in children Brain 130 Pt 10 2589 95 17827175 10.1093/brain/awm198 (Pubitemid 47511711)
40. B Banwell, et al. 2007 Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study Lancet Neurol 6 9 773 81 17689148 10.1016/S1474-4422(07)70196-5 (Pubitemid 47238663)
41. D Pohl, et al. 2006 High seroprevalence of Epstein-Barr virus in children with multiple sclerosis Neurology 67 11 2063 5 17159123 10.1212/01.wnl. 0000247665.94088.8d 1:STN:280:DC%2BD28jit1Krsg%3D%3D (Pubitemid 44967394)
42. E Waubant, et al. 2011 Common viruses associated with lower pediatric multiple sclerosis risk Neurology 76 23 1989 1995 21646624 10.1212/WNL. 0b013e31821e552a 1:STN:280:DC%2BC3MjgvV2guw%3D%3D
43. Y Mikaeloff, et al. 2009 Clinically observed chickenpox and the risk of childhood-onset multiple sclerosis Am J Epidemiol 169 10 1260 6 19329530 10.1093/aje/kwp039
44. Y Mikaeloff G Caridade S Assi, et al. 2007 Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination Brain 130 Pt 4 1105 10 17276994 (Pubitemid 47355586)
45. Y Mikaeloff, et al. 2009 Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood Neurology 72 10 873 80 18843097 10.1212/01.wnl.0000335762.42177.07
46. B Banwell, et al. 2006 Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis Neurology 66 4 472 6 16505297 10.1212/01.wnl. 0000198257.52512.1a 1:CAS:528:DC%2BD28XhtFeis7w%3D (Pubitemid 43739870)
47. •• Ghezzi A, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci, 2009. 30(3):193-9.
48. LB Krupp B Banwell S Tenembaum 2007 Consensus definitions proposed for pediatric multiple sclerosis and related disorders Neurology 68 16 Suppl 2 S7 12 17438241 10.1212/01.wnl.0000259422.44235.a8 (Pubitemid 46626001)
49. OV Bykova LM Kuzenkova OI Maslova 2006 The use of beta-interferon-1b in children and adolescents with multiple sclerosis Zh Nevrol Psikhiatr Im S S Korsakova 106 9 29 33 17069059 1:STN:280:DC%2BD28njtlSjsw%3D%3D
50. EA Yeh E Waubant LB Krupp, et al. 2011 Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis Arch Neurol 68 4 437 44 21149803 10.1001/archneurol.2010.325
51. A Ghezzi 2005 Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study Neurol Sci 26 Suppl 4 S183 6 16388355 10.1007/s10072-005-0512-8 (Pubitemid 43085208)
52. TA Yousry, et al. 2006 Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 9 924 33 16510746 10.1056/NEJMoa054693 1:CAS:528:DC%2BD28XitVertLs%3D
53. P Huppke, et al. 2008 Natalizumab use in pediatric multiple sclerosis Arch Neurol 65 12 1655 8 19064754 10.1001/archneur.65.12.1655
54. H Weiner, et al. 1993 Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group Neurology 43 910 8 8388090 1:STN:280:DyaK3s3mtFKisw%3D%3D (Pubitemid 23150561)
55. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet, 1991;337:441-6.
56. H Hartung, et al. 2002 Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial Lancet 360 2018 25 12504397 10.1016/S0140-6736(02)12023-X (Pubitemid 36026580)
57. R Ellis M Boggild 2009 Therapy-related acute leukemia with mitoxantrone: What is the risk and can we minimise it? Mult Scler 15 4 505 8 19251838 10.1177/1352458508100967 1:CAS:528:DC%2BD1MXmtlKlsrw%3D
58. AM Pascual, et al. 2009 Revision of the risk of secondary leukemia after mitoxantrone in multiple sclerosis populations is required Mult Scler 15 11 1303 10 19825889 10.1177/1352458509107015 1:CAS:528:DC%2BD1MXhsF2hs7zI
59. Andreasen A, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler, 2011 (Epub ahead of print).
60. BD Cakt, et al. 2010 Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study Am J Phys Med Rehabil 89 6 446 57 20216060 10.1097/PHM.0b013e3181d3e71f
61. U Dalgas, et al. 2010 Fatigue, mood and quality of life improve in MS patients after progressive resistance training Mult Scler 16 4 480 90 20194584 10.1177/1352458509360040 1:STN:280:DC%2BC3c3lsVahuw%3D%3D
62. R McCullagh, et al. 2008 Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study Clin Rehabil 22 3 206 14 18285430 10.1177/0269215507082283 (Pubitemid 351460989)